Radiation Oncology Journal

  • 제34권3호
  • /
  • Pages.209-215
  • /
  • 2016
  • /
  • 2234-1900(pISSN)
  • /
  • 2234-3156(eISSN)
대한방사선종양학회 (The Korean Society for Radiation Oncology)
권호 표지
DOI QR코드

DOI QR Code

Organ preservation with neoadjuvant chemoradiation in patients with orbit invasive sinonasal cancer otherwise requiring exenteration

  • Amsbaugh, Mark J. (Department of Radiation Oncology, University of Louisville) ;
  • Yusuf, Mehran (Department of Radiation Oncology, University of Louisville) ;
  • Silverman, Craig (Department of Radiation Oncology, University of Louisville) ;
  • Bumpous, Jeffrey (Department of Otolaryngology, University of Louisville) ;
  • Perez, Cesar A. (Department of Medicine, University of Louisville) ;
  • Potts, Keven (Department of Otolaryngology, University of Louisville) ;
  • Tennant, Paul (Department of Otolaryngology, University of Louisville) ;
  • Redman, Rebecca (Department of Medicine, University of Louisville) ;
  • Dunlap, Neal (Department of Radiation Oncology, University of Louisville)
  • 투고 : 2016.03.30
  • 심사 : 2016.06.21
  • 발행 : 2016.09.30
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

Purpose: We sought to determine if organ preservation (OP) with neoadjuvant chemoradiation (CRT) was feasible in patients with sinonasal cancer determined to require exenteration. Materials and Methods: Twenty patients were determined to require exenteration for definitive treatment from 2005 to 2014. Fourteen patients underwent OP and 6 patients received exenteration with adjuvant CRT. Exenteration free survival (EFS), locoregional control (LRC), progression-free survival (PFS), and overall survival (OS) were estimated. Results: Five patients (36%) receiving OP had complete disease response at time of surgery. With a median follow-up of 18.8 months, EFS was 62% at 2 years for patients undergoing OP. At 2 years, there were no significant differences in LRC, PFS or OS (all all p > 0.050) between the groups. Less grade 3 or greater toxicity was seen in patients undergoing OP (p = 0.003). Visual function was preserved in all patients undergoing OP. Conclusion: For patients with sinonasal cancer, OP may avoid exenteration, offering similar disease control and improved toxicity.

키워드

참고문헌

  1. Haerle SK, Gullane PJ, Witterick IJ, Zweifel C, Gentili F. Sinonasal carcinomas: epidemiology, pathology, and management. Neurosurg Clin N Am 2013;24:39-49. https://doi.org/10.1016/j.nec.2012.08.004
  2. Homma A, Oridate N, Suzuki F, et al. Superselective highdose cisplatin infusion with concomitant radiotherapy in patients with advanced cancer of the nasal cavity and paranasal sinuses: a single institution experience. Cancer 2009;115:4705-14. https://doi.org/10.1002/cncr.24515
  3. Hoppe BS, Stegman LD, Zelefsky MJ, et al. Treatment of nasal cavity and paranasal sinus cancer with modern radiotherapy techniques in the postoperative setting: the MSKCC experience. Int J Radiat Oncol Biol Phys 2007;67:691-702. https://doi.org/10.1016/j.ijrobp.2006.09.023
  4. Blanch JL, Ruiz AM, Alos L, Traserra-Coderch J, Bernal-Sprekelsen M. Treatment of 125 sinonasal tumors: prognostic factors, outcome, and follow-up. Otolaryngol Head Neck Surg 2004;131:973-6. https://doi.org/10.1016/j.otohns.2004.08.001
  5. Khademi B, Moradi A, Hoseini S, Mohammadianpanah M. Malignant neoplasms of the sinonasal tract: report of 71 patients and literature review and analysis. Oral Maxillofac Surg 2009;13:191-9. https://doi.org/10.1007/s10006-009-0170-8
  6. Suarez C, Llorente JL, Fernandez De Leon R, Maseda E, Lopez A. Prognostic factors in sinonasal tumors involving the anterior skull base. Head Neck 2004;26:136-44. https://doi.org/10.1002/hed.10358
  7. Carrau RL, Segas J, Nuss DW, et al. Squamous cell carcinoma of the sinonasal tract invading the orbit. Laryngoscope 1999;109(2 Pt 1):230-5. https://doi.org/10.1097/00005537-199902000-00012
  8. Imola MJ, Schramm VL Jr. Orbital preservation in surgical management of sinonasal malignancy. Laryngoscope 2002;112(8 Pt 1):1357-65. https://doi.org/10.1097/00005537-200208000-00007
  9. Kovacs AF, Eberlein K, Hulsmann T. Organ preservation treatment using TPF: a pilot study in patients with advanced primary and recurrent cancer of the oral cavity and the maxillary sinus. Oral Maxillofac Surg 2009;13:87-93. https://doi.org/10.1007/s10006-009-0159-3
  10. Larson DL, Christ JE, Jesse RH. Preservation of the orbital contents in cancer of the maxillary sinus. Arch Otolaryngol 1982;108:370-2. https://doi.org/10.1001/archotol.1982.00790540042011
  11. Nishino H, Ichimura K, Tanaka H, et al. Results of orbital preservation for advanced malignant maxillary sinus tumors. Laryngoscope 2003;113:1064-9. https://doi.org/10.1097/00005537-200306000-00028
  12. Reyes C, Mason E, Solares CA, Bush C, Carrau R. To preserve or not to preserve the orbit in paranasal sinus neoplasms: a meta-analysis. J Neurol Surg B Skull Base 2015;76:122-8.
  13. Sakashita T, Hayashi R, Homma A, et al. Multi-institutional retrospective study for the evaluation of ocular functionpreservation rates in maxillary sinus squamous cell carcinomas with orbital invasion. Head Neck 2015;37:537-42. https://doi.org/10.1002/hed.23639
  14. Papadimitrakopoulou VA, Ginsberg LE, Garden AS, et al. Intraarterial cisplatin with intravenous paclitaxel and ifosfamide as an organ-preservation approach in patients with paranasal sinus carcinoma. Cancer 2003;98:2214-23. https://doi.org/10.1002/cncr.11771
  15. Rajapurkar M, Thankappan K, Sampathirao LM, Kuriakose MA, Iyer S. Oncologic and functional outcome of the preserved eye in malignant sinonasal tumors. Head Neck 2013;35:1379-84.
  16. Marcial VA. Ninth annual del Regato lecture: optimal multidisciplinary management of head and neck cancer. Int J Radiat Oncol Biol Phys 1987;13:393-401. https://doi.org/10.1016/0360-3016(87)90014-9
  17. Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009;45:228-47. https://doi.org/10.1016/j.ejca.2008.10.026
  18. Kreppel M, Danscheid S, Scheer M, et al. Neoadjuvant chemoradiation in squamous cell carcinoma of the maxillary sinus: a 26-year experience. Chemother Res Pract 2012;2012:413589.
  19. Kim JH, Lee YS, Chung YS, et al. Treatment outcomes of concurrent chemoradiotherapy for locally advanced sinonasal squamous cell carcinoma: a single-institution study. Acta Otolaryngol 2015;135:1189-95. https://doi.org/10.3109/00016489.2015.1061697
  20. Al-Mamgani A, van Rooij P, Mehilal R, Tans L, Levendag PC. Combined-modality treatment improved outcome in sinonasal undifferentiated carcinoma: single-institutional experience of 21 patients and review of the literature. Eur Arch Otorhinolaryngol 2013;270:293-9. https://doi.org/10.1007/s00405-012-2008-5
  21. Kang JH, Cho SH, Kim JP, et al. Treatment outcomes between concurrent chemoradiotherapy and combination of surgery, radiotherapy, and/or chemotherapy in stage III and IV maxillary sinus cancer: multi-institutional retrospective analysis. J Oral Maxillofac Surg 2012;70:1717-23. https://doi.org/10.1016/j.joms.2011.06.221
  22. Duthoy W, Boterberg T, Claus F, et al. Postoperative intensitymodulated radiotherapy in sinonasal carcinoma: clinical results in 39 patients. Cancer 2005;104:71-82. https://doi.org/10.1002/cncr.21100

피인용 문헌

  1. Sinonasal Squamous Cell Carcinoma, a Narrative Reappraisal of the Current Evidence vol.13, pp.11, 2016, https://doi.org/10.3390/cancers13112835
  2. Orbital exenteration and reconstruction in a tertiary UK institution: a 5-year experience vol.40, pp.4, 2016, https://doi.org/10.1080/01676830.2020.1775262
  3. Surgical Management of Sinonasal Cancers: A Comprehensive Review vol.13, pp.16, 2016, https://doi.org/10.3390/cancers13163995